Michele Stansfield
Michele is the co-founder and CEO of Cauldron. She was the driving force behind Cauldron’s management acquisition of Agritechnology, a bioscience company based in regional Australia that developed the proprietary hyper-fermentation technology at Cauldron’s core. Having served as Agritechnology’s General Manager for over a decade, using microbes to produce vaccines, food, feed and fuel, Michele has industry-leading expertise in the scale-up and commercialization of continuous fermentation biomanufacturing. With a background in biomedical science and cellular and molecular biology, Michele started her career with Pfizer focused on a novel pharmaceutical therapy used in the pork industry. Michele holds a BSc (Honours) in Biomedical Science, Cellular and Molecular Biology from the University of Western Sydney.
Cauldron Ferm
Continuous Fermentation – How Close Is It to Commercial Reality?
-
Continuous fermentation has significant potential to lower the cost of biomanufacturing, but how close to commercial reality is the technology? A group of industry experts will dig into the state of technology development and potential paths to implementation.
